Tatva Chintan Pharma Chem Limited (TATVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tatva Chintan Pharma Chem Limited (TATVA) has a cash flow conversion efficiency ratio of 0.019x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs135.54 Million ≈ $1.47 Million USD) by net assets (Rs7.27 Billion ≈ $78.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TATVA net asset quality index to measure how much of total assets are equity-financed.
Tatva Chintan Pharma Chem Limited - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Tatva Chintan Pharma Chem Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Tatva Chintan Pharma Chem Limited cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Tatva Chintan Pharma Chem Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tatva Chintan Pharma Chem Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Waluer Information Technology Co. Ltd. A
SHE:301380
|
-0.009x |
|
Shenzhen Longli Technology Co Ltd Class A
SHE:300752
|
0.018x |
|
Prothena Corporation plc
NASDAQ:PRTA
|
-0.138x |
|
Energy Recovery Inc
NASDAQ:ERII
|
0.114x |
|
Guangzhou Huayan Precision Machinery Co.Ltd.
SHE:301138
|
0.052x |
|
AngioDynamics Inc
NASDAQ:ANGO
|
-0.018x |
|
Diageo PLC
LSE:DGE
|
0.082x |
|
Smartoptics Group AS
OL:SMOP
|
0.323x |
Annual Cash Flow Conversion Efficiency for Tatva Chintan Pharma Chem Limited (2018–2025)
The table below shows the annual cash flow conversion efficiency of Tatva Chintan Pharma Chem Limited from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Tatva Chintan Pharma Chem Limited.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs7.39 Billion ≈ $79.90 Million |
Rs246.71 Million ≈ $2.67 Million |
0.033x | -74.90% |
| 2024-03-31 | Rs7.37 Billion ≈ $79.71 Million |
Rs980.44 Million ≈ $10.60 Million |
0.133x | +146.47% |
| 2023-03-31 | Rs5.15 Billion ≈ $55.67 Million |
Rs277.83 Million ≈ $3.00 Million |
0.054x | +25.29% |
| 2022-03-31 | Rs4.73 Billion ≈ $51.16 Million |
Rs203.78 Million ≈ $2.20 Million |
0.043x | -70.60% |
| 2021-03-31 | Rs1.66 Billion ≈ $17.95 Million |
Rs243.19 Million ≈ $2.63 Million |
0.147x | -31.87% |
| 2020-03-31 | Rs1.18 Billion ≈ $12.73 Million |
Rs253.12 Million ≈ $2.74 Million |
0.215x | +133.02% |
| 2019-03-31 | Rs797.00 Million ≈ $8.62 Million |
Rs73.56 Million ≈ $795.52K |
0.092x | -47.56% |
| 2018-03-31 | Rs591.56 Million ≈ $6.40 Million |
Rs104.12 Million ≈ $1.13 Million |
0.176x | -- |
About Tatva Chintan Pharma Chem Limited
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and br… Read more